Please login to the form below

Not currently logged in
Email:
Password:

Merck to acquire Avecia Biologics in the UK

Merck has announced they are to acquire British biotechnology group, Avecia Biologics, through UK affiliate, MSD

Merck has announced they are to acquire British biotechnology group, Avecia Biologics, through UK affiliate, Merck Sharp and Dohme (MSD). Financial details remain undisclosed.

The agreement will see Merck acquire the Billingham based business, which has been providing contract development and manufacturing services in the fields of microbial-derived biopharmaceuticals since 1998, as well as all its assets. These include the company's process development and scale-up, manufacturing, quality and business support operations.

Merck also intend to honour all standing contractual agreements and engage in discussions with individual customers regarding their specific ongoing and future biological process development and manufacturing needs after the transaction is finalised.

John T McCubbins, senior vice president, biologics and therapeutic protein operations, Merck manufacturing division said: "At Merck we continue to execute on our strategy of expanding our biopharmaceutical expertise and manufacturing capacity.

"This transaction follows an initial strategic development and supply relationship with Avecia Biologics and will provide us with an operational facility staffed by an experienced workforce that is highly skilled in a broad portfolio of bioprocess systems."

Closing of the transaction is subject to regulatory approval, as well as other customary closing conditions. The Oligomedicines Business of the Avecia group based in the US does not form part of this transaction.


Merck announce new executive vice president
Merck has also announced the appointment of Dr Michael Rosenblatt as executive vice president and chief medical officer, effective immediately.

The Fuller Albright Award winner and former director of the Harvard-MIT division of health sciences and technology will become the company's primary voice to the global medical community and will be responsible for bringing a focus to Merck's worldwide medical activities.


 

17th December 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics